Financial News

Recent Quotes

My Watchlist

Indicators

Overview

Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass

By: TalkMarkets

February 11, 2023 at 15:20 PM EST

CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global rights for its TLR8 agonist to GlaxoSmithKline.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Financial News

Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass

Popular Pages